Abstract:Numerous peptides inhibit the entry of enveloped viruses into cells. Some of these peptides have been shown to inhibit multiple unrelated viruses. We have suggested that such broad-spectrum antiviral peptides share a property called interfacial activity; they are somewhat hydrophobic and amphipathic, with a propensity to interact with the interfacial zones of lipid bilayer membranes. In this study, we further tested the hypothesis that such interfacial activity is a correlate of broad-spectrum antiviral activity. In this study, several families of peptides, selected for the ability to partition into and disrupt membrane integrity but with no known antiviral activity, were tested for the ability to inhibit multiple diverse enveloped viruses. These include Lassa pseudovirus, influenza virus, dengue virus type 2, herpes simplex virus 1, and nonenveloped human adenovirus 5. Various families of interfacially active peptides caused potent inhibition of all enveloped viruses tested at low and submicromolar concentrations, well below the range in which they are toxic to mammalian cells. These membrane-active peptides block uptake and fusion with the host cell by rapidly and directly interacting with virions, destabilizing the viral envelope, and driving virus aggregation and/or intervirion envelope fusion. We speculate that the molecular characteristics shared by these peptides can be exploited to enable the design, optimization, or molecular evolution of novel broad-spectrum antiviral therapeutics.IMPORTANCE New classes of antiviral drugs are needed to treat the ever-changing viral disease landscape. Current antiviral drugs treat only a small number of viral diseases, leaving many patients with established or emerging infections to be treated solely with supportive care. Recent antiviral peptide research has produced numerous membrane-interacting peptides that inhibit diverse enveloped viruses in vitro and in vivo Peptide therapeutics are becoming more common, with over 60 FDA-approved peptides for clinical use. Included in this class of therapeutics is enfuvirtide, a 36-residue peptide drug that inhibits HIV entry/fusion. Due to their broad-spectrum mechanism of action and enormous potential sequence diversity, peptides that inhibit virus entry could potentially fulfill the need for new antiviral therapeutics; however, a better understanding of their mechanism is needed for the optimization or evolution of sequence design to combat the wide landscape of viral disease.

The Research Progress of Antiviral Peptides

Antiviral peptides as promising therapeutic drugs

Virus-Derived Peptides for Clinical Applications

Broad-Spectrum Antiviral Entry Inhibition by Interfacially Active Peptides

The Role of Peptides in Combatting HIV Infection: Applications and Insights

Broad‐Spectrum Antiviral Peptides and Polymers

Method and Progress of the Research on Virus Affinity Peptide

Amino Acid and Peptide‐Based Antiviral Agents

Research progress in the mechanism of host defense peptides antagonizing viral infection

Multitalented Synthetic Antimicrobial Peptides and Their Antibacterial, Antifungal and Antiviral Mechanisms

Utilization of Antiviral Peptides in Treating Coronavirus Infection: An Overview

Plant-Derived Antimicrobial Peptides as Potential Antiviral Agents in Systemic Viral Infections

Antiviral peptides against SARS-CoV-2: therapeutic targets, mechanistic antiviral activity, and efficient delivery

Peptides as Therapeutic Agents for Dengue Virus

Antimicrobial peptides and other peptide-like therapeutics as promising candidates to combat SARS-CoV-2

Exploring the Efficacy of Peptides and Mimics against Influenza A Virus, Adenovirus, and Murine Norovirus

Medicinal Chemistry Insights into Antiviral Peptidomimetics

Current Progress in Antiviral Strategies.

Review and perspective on bioinformatics tools using machine learning and deep learning for predicting antiviral peptides

Protein- and Peptide-Based Virus Inactivators: Inactivating Viruses Before Their Entry Into Cells

Progress of Antimicrobial Peptides Research and Its Current Therapeutic Application